Help employers find you! Check out all the
MENLO PARK, Calif., April 3, 2014 /PRNewswire/ -- Corium International, Inc. (NASDAQ: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today the pricing of its initial public offering of 6,500,000 shares of common stock at a price to the public of $8.00 per share. The shares are scheduled to begin trading on the NASDAQ Stock Market on April 3, 2014 under the symbol "CORI". All of the shares of common stock are being offered by Corium. Corium has also granted the underwriters a 30-day option to purchase up to 975,000 additional shares of common stock at the initial public offering price.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and FBR Capital Markets & Co. are acting as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 2, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering was made solely by means of a prospectus. A copy of the final prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by email at email@example.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, or by email at firstname.lastname@example.org.
Investor and Media Contact:
Karen L. Bergman
SOURCE Corium International, Inc.